➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Mallinckrodt
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Anakinra - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for anakinra

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Assistance Publique Hopitaux De MarseillePhase 3
M.D. Anderson Cancer CenterPhase 1/Phase 2
Jon LampaPhase 2

See all anakinra clinical trials

Recent Litigation for anakinra

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
AMGEN INC v. SANDOZ INC.2018-06-26

See all anakinra litigation

PTAB Litigation
PetitionerDate
2015-06-02
2012-09-25

See all anakinra litigation

Pharmacology for anakinra

Company Disclosures: US Patents for anakinra

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Synergen, Inc. (Boulder, CO) 2008-12-24 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2020-07-29 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Synergen, Inc. (Boulder, CO) 2008-12-24 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2020-07-29 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Amgen Inc. (Thousand Oaks, CA) The Regents of the University of Colorado (Boulder, CO) 2022-02-22 RX company
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   Start Trial Synergen, Inc. (Boulder, CO) 2008-12-24 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for anakinra

These patents were identified by searching patent claims

Supplementary Protection Certificates for anakinra

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C00050 Luxembourg   Start Trial PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
00467 Netherlands   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
C/GB02/026 United Kingdom   Start Trial PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308
90038-9.L Sweden   Start Trial PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
0467 Netherlands   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
C0050 France   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.